Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
The current price of XVIPY is $6.54 USD — it has increased by +0% in the past 24 hours. Watch Xvivo Perfusion AB stock price performance more closely on the chart.
What is Xvivo Perfusion AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xvivo Perfusion AB stocks are traded under the ticker XVIPY.
When is the next Xvivo Perfusion AB earnings date?▼
Xvivo Perfusion AB is going to release the next earnings report on April 24, 2026.
What were Xvivo Perfusion AB earnings last quarter?▼
XVIPY earnings for the last quarter are 0.11 USD per share, whereas the estimation was 0.07 USD resulting in a +52.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xvivo Perfusion AB revenue for the last year?▼
Xvivo Perfusion AB revenue for the last year amounts to 236.82M USD.
What is Xvivo Perfusion AB net income for the last year?▼
XVIPY net income for the last year is 4.85M USD.
How many employees does Xvivo Perfusion AB have?▼
As of April 01, 2026, the company has 170 employees.
When did Xvivo Perfusion AB complete a stock split?▼
Xvivo Perfusion AB has not had any recent stock splits.
Where is Xvivo Perfusion AB headquartered?▼
Xvivo Perfusion AB is headquartered in Mölndal, US.